AI
China’s regulatory innovation for new biomedical technologies
The case pre-dates China's State Council Order No. 818 and highlights the critical need to establish clear regulatory frameworks for new biomedical technologies before widespread adoption occurs.
A six-year-old girl died last year after receiving an experimental brain-directed gene-editing therapy for a rare disorder in Shanghai, China (B. Borrell Science 393, 346–353; 2026).
- A fatal adverse event occurred in a clinical trial involving gene editing, underscoring urgent regulatory gaps.
- This incident happened prior to the implementation of State Council Order No. 818 but still demonstrates systemic risks.
- Researchers and regulators must collaborate urgently to define safety standards for emerging biotech therapies globally.